Actelion’s novel CRTH2 antagonist meets primary endpoint in Phase II study in … – Reuters (press release)

Actelion's novel CRTH2 antagonist meets primary endpoint in Phase II study in
Reuters (press release)
This study complements the positive proof-of-mechanism study in asthma reported in 2009. Together, these studies provide substantial information that will guide us in the further development of this compound and our follow-up molecules in allergic

and more »

View full post on asthma – Google News

Leave a Reply

Your email address will not be published. Required fields are marked *